Clinical and Experimental Hepatology
eISSN: 2449-8238
ISSN: 2392-1099
Clinical and Experimental Hepatology
Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
3/2025
vol. 11
 
Share:
Send email
Share:
Original paper

Impact of the removal of treatment barriers on the microelimination of chronic hepatitis C in Slovak prisons: experience from real-life settings

Ivana Hockicková
1
,
Ján Hockicko
1
,
Peter Jarčuška
2
,
Sylvia Dražilová
2
,
František Lami
1
,
Patrícia D. Lenártová
1
,
Pavol Mrážik
3
,
Adrián Gábor
4
,
Pavol Kristian
1

  1. Department of Infectology and Travel Medicine, Faculty of Medicine, P.J. Šafárik University, and L. Pasteur University Hospital, Košice, Slovakia
  2. 2nd Department of Internal Medicine, Faculty of Medicine, P.J. Šafárik University, and L. Pasteur University Hospital, Košice, Slovakia
  3. Correctional Facility, Košice-Šaca, Slovakia
  4. Remand Prison and Correctional Facility, Košice, Slovakia
Clin Exp HEPATOL 2025; 11, 3: 271–278
DOI: https://doi.org/10.5114/ceh.2025.154078
Online publish date: 2025/09/16
Article file
- Impact.pdf  [0.13 MB]
Get citation
 
PlumX metrics:
 
1. World Health organization. Hepatitis C. https://www.who.int/news-room/fact-sheets/detail/hepatitis-c.
2. Flisiak R, Frankova S, Grgurevic I, et al. How close are we to hepatitis C virus elimination in Central Europe? Clin Exp Hepatol 2020; 6: 1-8.
3. Flisiak R, Zarębska-Michaluk D, Frankova S, et al. Is elimination of HCV in 2030 realistic in Central Europe. Liver Int 2021; 41 Suppl 1: 56-60.
4. European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; Clinical Practice Guidelines Panel: Chair; EASL Governing Board representative; Panel members. EASL recommendations on treatment of hepatitis C: Final update of the series. J Hepatol 2020; 73: 1170-1218.
5. Dolan K, Wirtz AL, Moazen B, et al. Global burden of HIV, viral hepatitis, and tuberculosis in prisoners and detainees. Lancet 2016; 388: 1089-1102.
6. Larney S, Kopinski H, Beckwith CG, et al. Incidence and prevalence of hepatitis C in prisons and other closed settings: results of a systematic review and meta-analysis. Hepatology 2013; 58: 1215-1224.
7. Global health sector strategies on, respectively, HIV, viral hepatitis and sexually transmitted infections for the period 2022-2030. World Health Organization, Geneva 2022.
8. Report on the Number and Composition of Accused and Convicted Persons in Pre-Trial Detention Centers and Correctional Facilities as of February 1, 2025, Ministry of Justice of the Slovak Republic. Available in Slovak language. https://www.zvjs.sk/sk/statistiky.
9. Bočáková J, Králiková L. Hepatitis C elimination in the first prison in Slovakia. INSHU October 8-11, 2024. Poster #152.
10. Gazdíková K, Gazdák F, Fejdiová K, et al. Prevalencia hepatitídy C v bežnej populácii a v rizikových skupinách na Slovensku. Via Practica 2011; 8: 246-249.
11. Statistical data on treatment of HCV positive prisoners. Report of the General Directorate of the Prison and Justice Guard Corps, 2019. Available in Slovak language. https://www.uvzsr.sk/documents/d/uvz/programy-a-akcne-plany-prevencie-a-kontroly-infekcnych-v-slovenskej-republike-na-roky-2024-2026-pdf.
12. Flisiak R, Zarębska-Michaluk D, Ciupkeviciene E, et al. HCV elimination in Central Europe with particular emphasis on microelimination in prisons. Viruses 2022; 14: 482.
13. Amendment to Act No. 580/2024 of the Collection of Acts on Health Insurance. Available in Slovak language. https://www.slov-lex.sk/ezbierky/pravne-predpisy/SK/ZZ/2004/580/vyhlasene_znenie.html.
14. European Centre for Disease Prevention and Control. Hepatitis C. In: ECDC. Annual epidemiological report for 2022. ECDC, Stockholm 2024.
15. Werling K, Hunyady B, Makara M, et al. Hepatitis C screening and treatment program in Hungarian prisons in the era of direct acting antiviral agents. Viruses 2022; 14: 308.
16. Tejera-Pérez RJ, Iglesias-Gómez A, Oliva-Oliva A, et al. Real-life experience of hepatitis C treatment in a Spanish prison. Rev Esp Quimioter 2022; 35: 273-278.
17. Daw MA, El-Bouzedi AA, Ahmed MO, et al. Geographic integration of hepatitis C virus: A global threat. World J Virol 2016; 5: 170-182.
18. Sojak L, Simekova K, Piesecka L, et al. Attitudes and perspectives of people living with human immunodeficiency virus: Findings from the positive perspectives survey in Slovakia. Int
19. J Public Health 2021; 66: 642869.
20. Office of Public health authority of the Slovak republic. Immunological overview in Slovak republic in 2018 (seroprevalence 364 study). Final report. Available at: https://old.uvzsr.sk/index.php?option=com_content&view=category&lay-365 out=blog&id=211&Itemid=142
21. Marshall AD, Cunningham EB, Nielsen S, et al. International Network on Hepatitis in Substance Users (INHSU). Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe. Lancet Gastroenterol Hepatol 2018; 3: 125-133.
22. Grebely J, Dore GJ, Zeuzem S, et al. Efficacy and safety of sofosbuvir/velpatasvir in patients with chronic hepatitis C virus infection receiving opioid substitution therapy: analysis of phase 3 ASTRAL trials. Clin Infect Dis 2016; 63: 1479-1481.
23. Grebely J, Dalgard O, Conway B, et al. Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial. Lancet Gastroenterol Hepatol 2018; 3: 153-161.
24. Crowley D, Van Hout MC, Lambert JS, et al. Barriers and facilitators to hepatitis C (HCV) screening and treatment – a description of prisoners’ perspective. Harm Reduct J 2018; 15: 62-67.
25. Stöver H, Tarján A, Horváth G, et al. The state of harm reduction in prisons in 30 European countries with a focus on people who inject drugs and infectious diseases. Harm Reduct J 2021; 18: 67.
Copyright: © Clinical and Experimental Hepatology. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0). License (http://creativecommons.org/licenses/by-nc-sa/4.0/) enables reusers to distribute, remix, adapt, and build upon the material in any medium or format for noncommercial purposes only, and only so long as attribution is given to the creator. If you remix, adapt, or build upon the material, you must license the modified material under identical terms.
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2025 Termedia Sp. z o.o.
Developed by Bentus.